Japan Medical Dynamic Marketing Inc

Japan Medical Dynamic Marketing Inc has a market price of 530 JPY, with a market cap of 13.97 billion JPY and a price-to-book ratio of 0.57, indicating a discount to tangible book value. The company holds 3.18 billion JPY in cash and equivalents but has 3.29 billion JPY in long-term debt, resulting in a net cash position of -104.29 million JPY. The current ratio of 3.29 suggests strong short-term liquidity, but the negative free cash flow of -835.28 million JPY and operating income of -275.09 million JPY highlight operational cash flow challenges. Profitability metrics are weak, with a return on equity of -1.87% and return on assets of -1.37%, both significantly below industry norms for medical equipment firms. Gross profit of 15.65 billion JPY represents 62.3% of revenue, but operating losses and negative net income of -461.80 million JPY indicate margin compression or cost overruns. The company operates in two segments: Japan and America. The Japan segment focuses on importing and selling orthopedic products, while the America segment involves development and manufacturing. Revenue concentration is not disclosed, but the presence of a U.S. subsidiary suggests exposure to North American markets. Outlook data is not provided, but the company’s recent performance shows a revenue of 25.11 billion JPY, slightly above the mean analyst estimate of 24.5 billion JPY. However, the last actual EPS of -17.54 JPY contrasts sharply with the mean estimate of 16.30 JPY, signaling a significant earnings shortfall. Risk factors include a medium liquidity risk due to negative free cash flow and a net cash deficit. The dilution risk is low, with no near-term pressure from share issuance or ATM programs. However, the company’s operating losses and debt-to-equity ratio of 0.13 suggest potential refinancing or margin improvement pressures. Recent filings and transcripts are not provided, but the company’s 2024-04-01 financial snapshot indicates a need for operational restructuring or cost optimization to address its negative net income and operating losses.